C12N 2710/16652
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2710/16652 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 18 US grants and 31 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 31
- Assignees
- 25
- Inventors
- 56
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 0 |
| 2019 | 2 | 3 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 4 |
| 2023 | 1 | 2 |
| 2024 | 2 | 3 |
| 2025 | 1 | 6 |
| 2026 | 2 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant oncolytic virus, preparation method therefor, use thereof and medicine thereof26 May 2026US 12,636,329 B2
- Herpesvirus with modified glycoprotein H for propagation in a cell21 Apr 2026US 12,606,801 B2Alma Matter Studiorum Universita Di Bologna
- Means and methods for treating herpesvirus infection16 Sep 2025US 12,414,989 B2Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- Vero cell lines stably expressing HSV ICP0 protein24 Sep 2024US 12,098,380 B2The Brigham and Women S Hospital, Inc.
- Attb cell line, transgenic cell lines derived therefrom, and methods of making the same21 May 2024US 11,987,805 B2Albert Einstein College of Medicine
- High-transducing hsv vectors10 Sep 2026US 2026/0265775 A1PeriphaGen, Inc.
- Compositions and systmes for herpes simplex virus packaging and uses thereof28 May 2026US 2026/0146259 A1Opentrons Labworks Inc.
- Recombinant herpes simplex virus-2 expressing glycoprotein d and b antigens4 Dec 2025US 2025/0367279 A1The Brigham and Women S Hospital, Inc.
- Hsv vectors21 Aug 2025US 2025/0263741 A1PeriphaGen, Inc.
- Systems and methods for viral transfection of cells in a bioreactor7 Aug 2025US 2025/0250549 A1Culture Biosciences, Inc.
Most cited
By later US patents
- Herpes Simplex virus as a vector100US 5,288,641 AArch Development Corporation · 1994
- Herpes simplex virus strains for gene transfer71US 5,804,413 AUniversity of Pittsburgh—Of the Commonwealth System of Higher Education · 1998
- Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use42US 5,658,724 AUniversity of Pittsburgh—Of the Commonwealth System of Higher Education · 1997
- Neural stem cells and use thereof for brain tumor therapy14US 7,186,409 B2Children's Medical Center Corporation · 2007
- Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production12US 10,174,341 B2University of Pittsburgh—Of the Commonwealth System of Higher Education · 2019